Combined HPV extended genotyping and automated visual evaluation

Combined HPV extended genotyping and automated visual evaluation has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Nov 1, 2026: “Extended genotyping of human papillomavirus and AI-assisted cervical visual evaluation for prediction of cervical precancer in nine resource-limited settings (PAVE): a cross-sectional study”.

Exposure

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on combined HPV extended genotyping and automated visual evaluation

At a glance

The findings reach people, from one lab or study. 1 lab.

“The maximum AUC was 0·82 (95% CI 0·80–0·84) for CIN3+ diagnosed with ectocervical biopsy.”
Extended genotyping of human papillomavirus and AI-assisted cervical visual evaluation for prediction of cervical precancer in nine resource-limited settings (PAVE): a cross-sectional studyThe Lancet. Obstetrics, gynaecology, & women's health2026doi:10.1016/s3050-5038(26)00231-1
Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab
  • Funders: Cancer Moonshot and 3 more
  • Humans1

What is combined HPV extended genotyping and automated visual evaluation linked with?

1

Studies link combined HPV extended genotyping and automated visual evaluation with cervical intraepithelial neoplasia grade 3 or worse.

Cervical intraepithelial neoplasia grade 3 or worse

upin humans1

1 study
  1. Combined HPV extended genotyping and automated visual evaluation predicts cervical intraepithelial neoplasia grade 3 or worse in humans (CIN3+ diagnosed with ectocervical biopsy) (Maximum AUC 0.82 (95% CI 0.80–0.84)).

    HumansCIN3+ diagnosed with ectocervical biopsycervixfemales

More on Cervical intraepithelial neoplasia grade 3 or worse

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months